Danica J. Marrelli, OD, FAAO, shares highlights from the glaucoma panel, which she was part of during the 17th annual Controversies in Modern Eye Care meeting.
Danica J. Marrelli, OD, FAAO, shares key takeaways from her featured symposium, "Pearls in comanging glaucoma," which she co-presented during the 17th annual Controversies in Modern Eye Care symposium at the Skirball Cultural Center in Los Angeles, California.
This transcript has been edited for clarity.
Danica J. Marelli, OD, FAAO:
Hi, I'm Danica Marrelli, an optometrist from Houston, Texas, and today I was on part of the glaucoma panel.
I was talking about our traditional medical therapies and where there's really kind of an unmet need, where for really about 25 years, we haven't been paying attention medically to the trabecular meshwork in the conventional outflow pathway, but we have some newer medications that really target that. And it's really something that we need to be aware of so that we're targeting the main resistance to outflow area for our glaucoma patients.
I think it's very easy for doctors to get very set in their ways. We use the same medications over and over and a new medication comes out and you still don't know exactly where it fits. And so I hope that today's presentation kind of reminded [attendees] of these newer medications and the fact that they're really important. They work very well, patients tolerate them, and they definitely have a role in our medical management of glaucoma patients.